Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine
Authors:
- 13 October 2022
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 39 (1) , 105-112
Abstract
Objective: To assess the available clinical and economic evidence of erenumab vs onabotulinumtoxinA for chronic migraine (CM) and present de-novo indirect treatment comparisons (ITCs) based on available clinical trial data. Methods: We conducted ITCs based on results from the pivotal 295 trial (NCT02066415) of erenumab vs placebo and published aggregate data from the PREEMPT 1 (NCT00156910) and PREEMPT 2 (NCT00168428) trials of onabotulinumtoxinA vs placebo. ITCs were conducted for CM patients with and without prior administration of onabotulinumtoxinA and among CM patients with ≥3 prior preventive treatment failures. Efficacy was assessed based on responder rates of ≥50% reductions in monthly headache days (MHDs) and monthly migraine days (MMDs) as well as change from baseline in both MHDs and MMDs. Results: Among patients with CM, 140 mg erenumab was associated with a reduction of 1.2 MHD (p = 0.092) and a reduction of 1.0 MMD (p = 0.174) compared to onabotulinumtoxinA at Week 12. Among onabotulinumtoxinA-naïve patients, erenumab was associated with a reduction of 1.8 MHD (p = 0.026) and 1.4 MMD (p = 0.080) at Week 12. Among patients that had received ≥3 prior preventive treatments, the odds ratios comparing erenumab vs onabotulinumtoxinA were 1.7 for ≥50% responder rates based on reductions in MHD (p = 0.155) and 1.7 for ≥50% responder rates based on reductions in MMD (p = 0.140). Conclusion These findings suggest directional benefits (although not reaching the threshold of statistical significance) associated with erenumab vs onabotulinumtoxinA for the preventive treatment of CM. Evidence from this study may inform healthcare stakeholders in treatment selection and optimization for patients with CM.Keywords
This publication has 48 references indexed in Scilit:
- Defining the Differences Between Episodic Migraine and Chronic MigraineCurrent Pain and Headache Reports, 2011
- OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraineNeurology, 2011
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical ProgramHeadache: The Journal of Head and Face Pain, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia, 2010
- Migraine prevalence by age and sex in the United States: A life-span studyCephalalgia, 2010
- The Burden of Migraine in the United States: Current and Emerging Perspectives on Disease Management and Economic AnalysisValue in Health, 2009
- Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population‐Based StudyHeadache: The Journal of Head and Face Pain, 2008
- Headache Impact Test-6 (HIT-6) Scores for Migraine Patients: Their Relation to Disability as Measured from a Headache DiaryJournal of Clinical Neurology, 2008
- Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open‐label studyOtolaryngology–Head and Neck Surgery, 2000